Company Overview
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +274.52% |
| 6 Months: | +51.75% |
| 3 Months: | -20.88% |
| 1 Month: | -12.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)35.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 31.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MBX MBX Biosciences, Inc. R2KR3KPHARMA | 48.50 | -20.46 | $2.34B | 0.00% | -26.53% | -33.17% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -10.95M | -13.31M | -16.66M | -19.61M | -26.53M | -21.80M | -23.93M | -27.27M | -40.93M |
| Net Income | -5.95M | -7.61M | -10.16M | -12.34M | -15.86M | -18.14M | -23.88M | -19.41M | -21.62M | -23.52M | -37.09M |
| Diluted EPS | - | - | -9.40 | -10.26 | -12.62 | -2.78 | -0.71 | -0.58 | -0.63 | -0.50 | -0.78 |
| R&D Expense | - | - | 9.07M | 11.05M | 14.40M | 16.75M | 22.41M | 17.72M | 19.27M | 18.47M | 30.98M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Income | -35.31M | -68.19M | -98.06M |
| Net Income | -32.56M | -61.92M | -86.97M |
| Diluted EPS | -31.96 | -5.82 | -2.38 |
| R&D Expense | 28.53M | 57.41M | 79.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 84.18M | 268.54M | 385.14M |
| Total Equity | -42.60M | -72.47M | 257.44M | 369.22M |
| Cash & Equivalents | - | 30.52M | 49.35M | 75.29M |
| Total Liabilities | - | 4.29M | 11.09M | 15.92M |
| Current Liabilities | - | 3.93M | 11.05M | 15.49M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -31.98M | -54.68M | -79.95M |
| Investing Cash Flow | -30.93M | -160.59M | -83.70M |
| Financing Cash Flow | 69.22M | 234.10M | 189.59M |
| Capital Expenditure | -129.00K | -874.00K | -1.93M |
| Free Cash Flow | -32.11M | -55.55M | -81.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | 44.9% | -24.1% | -23.6% |
| ROCE % | -44.0% | -26.5% | -26.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 13.81% | 6.65M | $354.15M |
| 2 | FMR, LLC | 11.05% | 5.32M | $283.39M |
| 3 | Wellington Management Group, LLP | 10.34% | 4.98M | $265.00M |
| 4 | NEA Management Company, LLC | 7.51% | 3.61M | $192.44M |
| 5 | Orbimed Advisors LLC. | 7.12% | 3.43M | $182.55M |
| 6 | Blackrock Inc. | 6.90% | 3.32M | $176.95M |
| 7 | Paradigm Biocapital Advisors LP | 5.21% | 2.51M | $133.53M |
| 8 | NVP Associates, LLC | 4.44% | 2.14M | $113.74M |
| 9 | Deep Track Capital, Lp | 3.60% | 1.73M | $92.24M |
| 10 | Polar Capital Holdings PLC | 3.34% | 1.61M | $85.64M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MBX
Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPbll5SGpQYUdOajVoR0Q0ZFpUOFhaNHdmMlY3ZUgzQ0g2WmlTZmp2RFpoSHF5bWExSUdSTW9VWjliYk9aZk5ZcHAxbVpfOG5YRDliTnJOSl9GNVMzZHlJR3JCTm9lUXBFQVIzLWJNU0QzcHNDM0RqbXYzNE81VW1XVUF1V2pCVGFkWXU4a3…
MBX Biosciences appoints Peter Radovich to board as independent director By Investing.com - Investing.com Canada
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNQklBSFBTRUxmRUVQYXFIV0E5S0F6a3lHTXFGc1hvdjBocFVRYzJrZDFnX21BVDNuenFXaTY3amxWLTZERUEyelE2d0RZZWR5UlgybEtjSXJVejhVYWtvdDA4WnlOX1lRUDNLb29NWFY3ZV9Pc09pOEt0dlRDcFlGS3hLdVR4RGJOWjVQY2…
MBX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBvLS1wM0Qta2V6MjlMa1Ytd0VMN2FSQjdtbi0zNjQ5ZFpWV3ZHUTZYOTZfOWUta19ybUk1WlhXdEUwcmlibFIzRm1qaXcwcmo4d08tY01zUHQ5OEt5MzNPSlV4RHBlSkJjYUJyVW4xbndmdEt3b3ZOZQ?oc=5" target="_blank">MBX F…
MBX Biosciences (NasdaqGS:MBX) Stock Forecast & Analyst Predictions - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPUmhFRUVES3A5UG5xUWl0OGRJY0dhX2IzbzNESXR1c3VfSHBFQnBZWEZyX0pkOF9kTHVid2ZncG51cVdrc1VyVkJERDNmZ0g2VHlXTDM3a0M1ZGprZWg2LTNvMTlQVHpPVEdHajhIT2JYeEI1NlhlTVIzVE5iN3ktaWIwbklsSWh1WG55cm…
MBX Biosciences, Inc. (NASDAQ:MBX) Stock Has Average Price Target of $83.89 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOSjFtZVJCN0NsNE5pUHBOQnVMWEVGUFZtbDVNVUVObHFqbUVMektGZ0xyQm03bU5QM1RwajU2LTY1T0dKUkVqMUgwbC1ETzloY2pKS3d5ZjFXVVhuN3RqWlhKQlVFLUVvMVhLV0hqR0NfM1FxV05RYk9ua1lDeXE3UlVjNS1VWVB3by1mej…
Form 8K MBX Biosciences Inc For: 22 October By Investing.com - Investing.com India
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOZ3JSQVE0dUUyZXMtV2dxSmEwOFp1S2ZUVVRvb3IxRHZlbzg0dWJyYWxmbHVDeFlBQmFrUXFoRTBsb3RaTU1POWh3alpQNzhiTGNTd3EzN0htdldWSFVmNEFsTzVuRDZIa29wUm1PVm10eFFaQm4xc3BUNnRfV044YmNCRXRvRlVkai1lTU…
MBX — Frequently Asked Questions
What is the current share price of MBX Biosciences, Inc. (MBX)?
As of 2026-10-23 16:27 PDT, MBX Biosciences, Inc. (MBX) trades at $48.50 on NasdaqGS. Its 52-week range is $9.74 to $70.70.
What is the market capitalisation of MBX?
MBX Biosciences, Inc. (MBX) has a market capitalisation of $2.34B on NasdaqGS.
What is the P/E ratio of MBX?
MBX trades at a trailing price-to-earnings (P/E) ratio of -20.46. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 7.37.
What is the return on equity (ROE) of MBX?
MBX has a return on equity (ROE) of -33.17%. Its return on capital employed (ROCE) is -26.53%.
Is MBX a good stock to buy?
This page provides a data-driven analysis of MBX Biosciences, Inc. (MBX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.